Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities

Imperial College, University of London, Royal Free Hospital, London, UK.
BJOG An International Journal of Obstetrics & Gynaecology (Impact Factor: 3.45). 05/2011; 119(1):20-5. DOI: 10.1111/j.1471-0528.2011.02970.x
Source: PubMed


To determine the risk of incident high-grade cervical intraepithelial neoplasia (CIN) in human papillomavirus (HPV) -positive women with low-grade cytological abnormalities who had a satisfactory normal colposcopy.
A retrospective follow-up study within the NHS HPV/LBC pilot studies.
The NHS Cervical Screening Programme in England.
A total of 1063 HPV-positive women with borderline or mild dyskaryosis who were negative at colposcopy from three sites within the NHS HPV/liquid-based cytology (LBC) pilot studies.
HPV triage took place in 2001/02. In 2009 all information on additional management on HPV-positive/colposcopy-negative women was requested. The rate of disease following a negative colposcopy was calculated, and survival analysis was used to determine whether the grade of referral cytology impacted on risk of subsequent disease. Results were compared with those in women from the same population who had not been HPV triaged.
Incident CIN2 or worse during follow up.
Of 1063 eligible women 965 had documented follow up. The cumulative rate of CIN2+ at 3 years in these women was 4.4% (95% CI 4.0-7.0%); the median time from normal colposcopy to final result was 27 months. There was no significant increase in the risk of future disease associated with age or initial cytology result.
The rate of subsequent high-grade CIN among colposcopically negative triaged women was sufficiently low to justify return to routine recall.

Download full-text


Available from: Rachel Sabine Kelly, Oct 02, 2014

Click to see the full-text of:

Article: Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities

169.87 KB

See full-text
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: UK colposcopy services are seeing increased workloads, a large proportion of which are follow-up appointments. The English Cervical Screening Programme HPV Special Interest Group identified five subcategories of colposcopy clinic patients who often require prolonged follow-up regimes for low-grade abnormalities. Human papillomavirus (HPV) testing has a high negative predictive value, meaning that HPV-negative women are at very low risk of underlying disease. Our objectives were to quantify the number of HPV-negative women in each study subcategory and to evaluate the number who could potentially be discharged from colposcopy on the basis of their results. Methods: Four colposcopy clinics prospectively identified women according to five categories over 12 months. All women underwent cytological testing and high-risk HPV (hrHPV) testing using the Hybrid Capture 2 test. Management outcomes and decisions based on a knowledge of the HPV status were recorded. Results: Data available on 755 women showed that 422/755 (55.9%) and 260/755 (34.4%) had persistent cervical intraepithelial neoplasia grade 1 (CIN1) (Category 1) or a minor abnormality following treatment (Category 2), respectively. In Categories 1 and 2, 51.7% and 60.2%, respectively, were hrHPV negative. The rates with biopsies of CIN2 or worse (CIN2+) across the two categories were 3/355 (0.8%) and 21/291 (7.0%) for hrHPV-negative and hrHPV-positive women, respectively. Conclusion: The incorporation of hrHPV testing within organized cervical screening programmes has been widely accepted. hrHPV testing for the clinical scenarios outlined in this study detects women who are hrHPV negative and therefore at low risk of underlying disease, potentially reducing anxiety and inconvenience for women and costs to colposcopy services.
    Cytopathology 08/2012; 24(5). DOI:10.1111/j.1365-2303.2012.01003.x · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The provision of guidance on cytology reporting and evaluation, first outlined in 1995 with the publication of Achievable Standards, Benchmarks for Reporting, and Criteria for Evaluating Cervical Cytopathology (ABC), and subsequently revised and expanded in a second edition in 2000, has been pivotal to the success of the National Health Service Cervical Screening Programme (NHSCSP), ensuring that standards are upheld, and that rigorous evaluation and quality assurance take place. In the last decade, major changes to the NHSCSP, notably the adoption of revised age ranges and screening intervals for all women in England, implementation of liquid-based cytology and, most recently, the decision to introduce high-risk human papillomavirus (HR-HPV) testing for triage of low-grade and borderline (equivalent to 'atypical') cytological abnormalities and test of cure after treatment of cervical intraepithelial neoplasia (CIN) determined that an updated version of ABC was required. The third edition of ABC recommends adoption, with minor modification, of the revised British Society for Clinical Cytology terminology and provides guidance on the management of abnormal cytology results linked to this terminology taking account of HR-HPV testing. To accommodate these changes, expanded result codes, which are electronic codes used to transfer management information to central computers for follow-up, call and recall of individual women, have been developed. Further guidance on specimen adequacy is also provided. Revised performance indicators are described and explained in a separate article by R. Blanks in this issue of Cytopathology. All the changes in ABC3 are designed to support the mission statement of the NHSCSP that 'the objective of cervical screening is to reduce cervical cancer incidence and mortality by screening with a high sensitivity for the detection of CIN2 or worse, whilst maintaining a high specificity'.
    Cytopathology 12/2012; 23(6):353-9. DOI:10.1111/cyt.12031 · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine outcomes in HrHPV-positive women with low grade cervical smears and normal or low grade initial colposcopy biopsy results in a cohort of women over a 2-year follow-up period. The revised National Cervical Screening (NCS) programme guidelines in New Zealand were implemented in October 2009. The guidelines state that women 30 years and older should undergo reflex HPV testing. If this test confirms the presence of HrHPV, women are to be referred for a colposcopic assessment. The guidelines do not mention what the follow-up period should be of women with HrHPV and normal or low grade abnormalities at colposcopy/biopsy. In this study we followed up women 30 years and older referred to Wellington Hospital from 1/10/2009 to 1/10/2011 with a LGSIL or ASC-US smear and positive HrHPV test. Those with a normal or low grade biopsy result were followed over a 2-year period to determine outcomes. Our study found that 4% of women with initial normal biopsy results and 15.2% with initial low grade results had progressed to high grade (CIN 2/3/invasion) over a 2-year follow-up period. During the same time period, 68% of women with an initial normal biopsy and 61% with a low grade biopsy had a normal colposcopy after 2 years. Twenty-eight percent of women with normal and 24% of those with initial with low grade biopsy continued to have LG abnormalities at 2 years of follow-up. Women 30 years and older who are HrHPV-positive and have low grade abnormalities at colposcopic biopsy may be followed up with a 12-month cervical smear rather than repeat colposcopy as the risk of progression to a high grade abnormality is low.
    The New Zealand medical journal 01/2013; 127(1390):38-44.
Show more